Sign up to save your podcasts
Or
Share “Right Drug, Right Patient, Right Price” - Using Data to Deliver Value w/ Pramod John
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
“Right Drug, Right Patient, Right Price” - Using Data to Deliver Value w/ Pramod John
Drug spending continues to escalate, accounting for an even bigger portion of total U.S. healthcare spend each year.
Why do we pay so much for medications? Are the drugs we buy truly worth the price we pay? How can we figure out the real value of a medication?
Pramod John joins the MTVA Board to help answer these questions and more. Guided by cold, hard data, Pramod expertly demystifies the drug market and pharmacy benefit ecosystem. His straightforward approach to pharmaceuticals is a stark departure from the overcomplicated acronyms and jargon common in the PBM space – in this episode, Pramod proves that you reallyCAN explain health care value in a straightforward way!
“It’s not the drug that you’re paying for, it’s the outcome.”
Pramod John is the Chairman and CEO ofVIVIO Health, a public benefit corporation using data to disrupt the typical PBM model. VIVIO’s mission is simple: to deliver the right drug for the right patient at the right price.
We discuss what drug data really mean, why Americans are overpaying for prescriptions, and how to move beyond our current broken system.
————————————
To learn more about topics discussed including the J&J lawsuit, PBMs and GLP-1 weight loss drugs, check out these other episodes of MTVA Unscripted:
J&J lawsuit
Wake-up Call: The Johnson & Johnson Prescription Pricing Scandal
From ERISA to CAA: How Has Employer’s Fiduciary Responsibility Changed Over Time?
PBMs
PBM Problems (Part 1): Who do Brokers and Consultants Really Work for? Risks for Plan Sponsors w/ ERISA attorney Paul Holmes
PBM Problems (Part 2): Transparency and Disrupting the Status Quo w/ Mutual Rx CEO Roy Wilkinson
PBM Problems (Part 3): Monopoly Power in Prescription Drug Markets w/ Luke Slindee
PBM Problems (Part 4): Challenges & Solutions for Independent Pharmacies w/ National Community Pharmacists Association
Market Forces Created Our Dysfunctional Health System. Now We Must Harness Them to Drive Change with Ge Bai, PhD, CPA
GLP-1s
GLP-1s Aren't Right for Everyone: Wiser Healthcare Consumption w/ Al Lewis
GLP-1 RA’s - Treating Obesity, the Potential, the Cost, and Coverage
————————————
We’re excited to welcome like-minded organizations and individuals to join the MTVA Membership program!
As a 501(c)(3) nonprofit, we rely on support from our grassroots network to advance our mission of creating a value-based health system with high-quality patient outcomes at a reasonable cost. Tax-deductible membership contributions help us enrich the healthcare environment with quality content – including this podcast – and robust platforms to fuel discussion, collaboration, and advocacy that lead to ground-breaking solutions.
For more information and to join us, visit our websitehttps://www.movingtovalue.org/membership.
All episodes of MTVA Unscripted can be foundhere.
View all episodes
By Moving to Value AllianceDrug spending continues to escalate, accounting for an even bigger portion of total U.S. healthcare spend each year.
Why do we pay so much for medications? Are the drugs we buy truly worth the price we pay? How can we figure out the real value of a medication?
Pramod John joins the MTVA Board to help answer these questions and more. Guided by cold, hard data, Pramod expertly demystifies the drug market and pharmacy benefit ecosystem. His straightforward approach to pharmaceuticals is a stark departure from the overcomplicated acronyms and jargon common in the PBM space – in this episode, Pramod proves that you reallyCAN explain health care value in a straightforward way!
“It’s not the drug that you’re paying for, it’s the outcome.”
Pramod John is the Chairman and CEO ofVIVIO Health, a public benefit corporation using data to disrupt the typical PBM model. VIVIO’s mission is simple: to deliver the right drug for the right patient at the right price.
We discuss what drug data really mean, why Americans are overpaying for prescriptions, and how to move beyond our current broken system.
————————————
To learn more about topics discussed including the J&J lawsuit, PBMs and GLP-1 weight loss drugs, check out these other episodes of MTVA Unscripted:
J&J lawsuit
Wake-up Call: The Johnson & Johnson Prescription Pricing Scandal
From ERISA to CAA: How Has Employer’s Fiduciary Responsibility Changed Over Time?
PBMs
PBM Problems (Part 1): Who do Brokers and Consultants Really Work for? Risks for Plan Sponsors w/ ERISA attorney Paul Holmes
PBM Problems (Part 2): Transparency and Disrupting the Status Quo w/ Mutual Rx CEO Roy Wilkinson
PBM Problems (Part 3): Monopoly Power in Prescription Drug Markets w/ Luke Slindee
PBM Problems (Part 4): Challenges & Solutions for Independent Pharmacies w/ National Community Pharmacists Association
Market Forces Created Our Dysfunctional Health System. Now We Must Harness Them to Drive Change with Ge Bai, PhD, CPA
GLP-1s
GLP-1s Aren't Right for Everyone: Wiser Healthcare Consumption w/ Al Lewis
GLP-1 RA’s - Treating Obesity, the Potential, the Cost, and Coverage
————————————
We’re excited to welcome like-minded organizations and individuals to join the MTVA Membership program!
As a 501(c)(3) nonprofit, we rely on support from our grassroots network to advance our mission of creating a value-based health system with high-quality patient outcomes at a reasonable cost. Tax-deductible membership contributions help us enrich the healthcare environment with quality content – including this podcast – and robust platforms to fuel discussion, collaboration, and advocacy that lead to ground-breaking solutions.
For more information and to join us, visit our websitehttps://www.movingtovalue.org/membership.
All episodes of MTVA Unscripted can be foundhere.